Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
University of Cambridge · Associates in Neurology · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,193
total citations
- FWCI
- 55.99
- Percentile
- 100%
- References
- 36
Citations per year
Authors
18- ACAlasdair ColesCorresponding
University of Cambridge
- CTCary Twyman
Associates in Neurology
- DLDouglas L. Arnold
NeuroRx Research (Canada), Montreal Neurological Institute and Hospital, McGill University
- JCJeffrey Cohen
Cleveland Clinic
- CCChristian Confavreux
Université Claude Bernard Lyon 1, Hospices Civils de Lyon
Topics & keywords
Topics
Keywords
- Alemtuzumab
- Multiple sclerosis
- Medicine
- Randomized controlled trial
- Disease
- Internal medicine
- Physical therapy
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.